A wave of clinical advances is expanding therapeutic options for aggressive cancers that have historically shown resistance to conventional treatment approaches. The momentum spans multiple modalities, from oncolytic viruses to cellular immunotherapy, signaling a broader shift in how the industry is addressing previously intractable malignancies.
Oncolytics Biotech's pelareorep achieved FDA Fast Track Designation for KRAS-mutant colorectal cancer following data showing doubled survival benefits compared to standard care. In parallel, Novocure secured regulatory approval for Optune Pax in pancreatic cancer, while Perspective Therapeutics reported encouraging interim results for its radiopharmaceutical VMT-α-NET. These developments reflect progress across distinct therapeutic platforms designed to circumvent traditional resistance mechanisms.
The advancement extends to cellular approaches, with ImmunityBio initiating Phase 2 testing of its CAR-NK cell therapy in combination with an IL-15 superagonist, and Nuvation Bio expanding Phase 3 enrollment for safusidenib in IDH1-mutant glioma. Collectively, these programs underscore the industry's diversified approach to tackling cancers with limited treatment alternatives, potentially reshaping standard-of-care protocols across multiple oncology indications.